502887-71-0

中文名称 MMP-9-IN-1

英文名称 MMP-9-IN-1

CAS 502887-71-0

分子式 C16H17F2N3O3S

分子量 369.39

MOL 文件 502887-71-0.mol

更新日期 2025/09/05 13:40:32

502887-71-0 结构式

基本信息物理化学性质安全数据图谱信息 MMP-9-IN-1价格(试剂级) 常见问题列表

基本信息

中文别名

化合物MMP-9-IN-1
N-(4-(二氟甲氧基)苯基)-2-((6-氧代-4-丙基-1,6-二氢嘧啶-2-基)硫代)乙酰胺

英文别名

OUN87710
MMP-9-IN-1
Acetamide, N-[4-(difluoromethoxy)phenyl]-2-[(1,6-dihydro-6-oxo-4-propyl-2-pyrimidinyl)thio]-

物理化学性质

密度1.37±0.1 g/cm3(Predicted)

储存条件Inert atmosphere,2-8°C

溶解度DMSO: 125 mg/mL (338.40 mM)

酸度系数(pKa)7.80±0.50(Predicted)

形态Solid

颜色White to off-white

安全数据

危险性符号(GHS) GHS hazard pictograms

GHS07

警示词警告

危险性描述H302-H315-H319-H335

防范说明P261-P305+P351+P338

图谱信息

MMP-9-IN-1(502887-71-0)核磁图(¹HNMR)

MMP-9-IN-1价格(试剂级)

报价日期	产品编号	产品名称	CAS号	包装	价格
2025/09/19	S0769	MMP-9-IN-1 MMP-9-IN-1	502887-71-0	5mg	2970元
2025/09/19	S0769	MMP-9-IN-1	502887-71-0	10mM (1mL in DMSO)	3251.43元
2025/09/19	S0769	MMP-9-IN-1 MMP-9-IN-1	502887-71-0	25mg	7944.3元

常见问题列表

生物活性

MMP-9-IN-1 (OUN87710)是一种 matrix metalloproteinase-9 (MMP-9) 的特异性抑制剂。MMP-9-IN-1 可选择性地靶向MMP-9的血红素(PEX)域，Kd值为2.1 μM。

靶点

Target	Value
MMP-9 (Cell-free assay)	2.1 μM(Kd)

体外研究

MMP-9-IN-1 (compound 2; 100 μM; 14 hours) does not cause notable cytotoxicity.
MMP-9-IN-1 (compound 2; 10 μM) significantly inhibits cell proliferation of HT-1080 and MDA-MB-435 cells.

Cell Cytotoxicity Assay

Cell Line:	COS-1 monkey epithelial cell lines
Concentration:	100 μM
Incubation Time:	24 hours
Result:	Treatment did not cause notable cytotoxicity.

Cell Proliferation Assay

Cell Line:	HT-1080 and MDA-MB-435 cancer cells expressing endogenous MMP-9
Concentration:	10 μM
Incubation Time:	9 days
Result:	Significant inhibition of cell proliferation.

体内研究

MMP-9-IN-1 (compound 2; 20 mg/kg; intraperitoneal and intratumoral injection alternately; 6 days/week; for 14 weeks) results in a profound delay in tumor growth in NCR-Nu mice bearing MDA-MB-435/GFP tumor.
MMP-9-IN-1 inhibits cancer cell metastasis in vivo.

Animal Model:	4-5 week-old female NCR-Nu mice bearing MDA-MB-435/GFP tumor
Dosage:	20 mg/kg
Administration:	Intraperitoneal and intratumoral injection alternately; 6 days/week; for 14 weeks,
Result:	Resulted in a profound delay in tumor growth. Inhibited cancer cell metastasis.